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Introduction: Mandibular advancement device (MAD) may represent a feasible choice in the treatment of
obstructive sleep apnea-hypopnea syndrome (OSAHS), in well selected patients.
Objective: The aim of this study is to assess the eﬃcacy of MAD in patients with OSAHS, using split night
polysomnography (SNP)
Method: We performed an auto controlled clinical trial to assess the eﬃcacy of MAD in 30 patients with snoring
and OSAHS. Clinical evaluation was made every 2 weeks to adjust treatment and observe changes in clinical
symptoms. Three-months after placement of the MAD, a SNP was performed, using the MAD in the second half
of the night, in order to compare the respiratory results.
Results: SNP show signiﬁcant changes with use of MAD (p < 0.05) such as: Decrease in Snore index (from
159.95 to 32.46/h) and in Apnea-hypopnea index (AHI, from 22.45 to 4.63/h), increase in oxygen saturation
(SaO2, from 89.98% to 91.39%) and somnolence improvement, using the Epworth Sleepiness Scale (from 14.4
to 4.6 points).
Conclusion: Our data supports that the use of MAD is an alternative in the management of OSAHS, in well
selected patients, used in a multidisciplinary fashion, and evaluated using a SNP.
1. Introduction
In recent years there has been an increase in the prevalence of Sleep
breathing disorders (SBD), such as snoring and Obstructive sleep
apnea-hypopnea syndrome (OSAHS) in worldwide [1]. For example,
a recent research study in Mexico City, the prevalence of OSAHS was
3.2% (2.4% females and 4.4% males). Similar to the prevalence
observed in the America population [2]. However, not all authors
had been found similar prevalence, Tuﬁk et al., found a higher
frequency of OSAHS, around 32% in one population of Sao Paulo,
Brazil [3].
OSAHS has a strong predominance in overweight and obese patients,
contributing to the risk of cardiovascular disease. Recent assessments
have shown, ﬁrst in obesity, there is an increasing the prevalence of this
pathology, this has attracted the attention of physicians [4], with the
recognizing of the need of a multidisciplinary management of sleep
breathing disorders such as snoring and OSAHS [5–8].
The contemporary physicians have more knowledge about this
condition, and in the diagnosis and in therapeutic choices, given that
the treatment should be individualized for each patient. The high costs
of the treatments, the lack of therapeutic adherence as well as
inadequate compliance of the patients, lead them to abandon their
treatment. For this reason, there is a need for therapeutic alternatives
which go beyond being eﬃcient, have lower prices, and increase the
possibility of long term success in the control of snoring and OSAHS
[3,7]. Among these alternatives, the Mandibular advancement device
(MAD) represent a less expensive choice in the management of SBD, as
they might be used as isolated treatment or along with other treatment
modalities, in well selected patients, by a multidisciplinary team,
including the otolaryngologist, the sleep medicine specialist and the
dentist [5,6,9].
MAD are oral appliances which are adapted to each dental arch,
upper and lower, and due to their shape, they displace the mandible
forward [10]. They can be ﬁxed or adjustable advancement, and given
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that the genioglossus muscle is inserted in the genni process, in the
anterior aspect of the mandible, with its protrusion, the retrolingual
space is increased, due to the genioglossus traction, which pulls the
tongue forward, avoiding collapse [11–13].
MAD are indicated in patients with snoring and with mild/
moderate sleep apnea, and in patients who do not tolerate the
treatment using Continuous positive airway pressure (CPAP) devices,
or those who are not good candidates for surgical management [14,15].
The obstruction area should be located at the retrolingual space.
Secondary eﬀects that some patients experience include: excessive
drooling, periodontal and dental disease, muscular pain and articular
discomfort. All these complaints decrease during the ﬁrst 2 weeks of
treatment [16–18].
MAD showed their eﬃcacy in a number of studies [19–22] but
there are few specialists who are able to manage this therapeutic
alternative. For this reason, there is not enough clinical evidence about
their results in several populations [23]. In many cases, MAD is not
adequately indicated, for a bad selection of patients, the lack of a
multidisciplinary approach, or for the lack of a proper clinical follow-
ing, leading to therapeutic fail. The international medical literature
regarding patients treated with MAD and assessed with this diagnostic
tool is underreported.
The aim in this study, was to test the proposed multidisciplinary
management of patients with OSAHS, with MAD, and an alternative
evaluation for their clinical following using a split night polysomno-
graphy (SNP).
2. Methods
2.1. Subjects
This was an auto-controlled clinical trial in 30 patients with OSAHS
from the Clinic of sleep disorders of the National University of Mexico
(UNAM), aimed to determine the therapeutic eﬃcacy of MAD in the
management of OSAHS, using a SNP. This study was approved by the
Ethics Committee of the Clinic of sleep disorders of UNAM.
Snoring and/or OSAHS patients were seen in the Otolaryngology
department. During clinical consultation, the OSAHS diagnosis was
made based on history, physical examination and diagnostic polysom-
nography (PSG) [24]. Patients who were candidates for MAD included
those who had collapse at the retrolingual space, determined by
examination, and the response watched on the mandibular protrusion
maneuver. Patients who required management for nasal pathology
were treated by the specialist. Patients were referred then to the
Dentistry department to continue with their evaluation, using dental
and skeletal tests, selecting only those cases who met the dentistry
criteria for MAD collocation.
During the ﬁrst appointment with the dentist, the tests included:
weight measurement, dental and articular evaluation, assessment of
the snoring noise according to the protrusion maneuver, and using a
temporal MAD. Measurements were taken for the evaluation of the
required advancement. We also used the Epworth Sleepiness Scale
(ESS) [25], and the evaluation of the Bed partner questionnaire after
Johnstone et al. of the snoring noise [26]. A second ESS and Bed
partner questionnaire was made 3 months after MAD use.
Odontological evaluation included soft and hard tissues examina-
tion of the oral cavity, looking for absence dental mobility, adequate
periodontal health and temporomandibular function, and taking care
of the absence of discomfort during mandibular movements. Patients
were excluded for any cranial disorder, so radiographic studies such as
cephalometric or dental studies could be needed.
Inclusion criteria were the presence of symptoms: snoring, daytime
sleepiness, fragmented sleep, witnessed apneas, and with diagnosis of
OSAHS (IAH< 30 events/h) in PSG. Patients were excluded if there
was edentulous, periodontal disease, or pain with protrusion maneu-
ver.
The scores of Epworth sleepiness scale were also evaluated.
Institutional ethics committee approval was obtained and informed
consent was obtained from all patients according to Declaration of
Helsinki.
2.2. Principles for the placement of MAD
The patient must have good oral hygiene and six teeth on each arch,
with healthy posterior on each quadrant, that keep the splint on place.
There will be no discomfort when doing movement border to border or
for mandibular protrusion (maximum protrusive < 6 mm). This is
important, because this will be the ﬁnal splint position. Once the
patients were enrolled, they came next week for the splint collocation.
For this device, to be eﬀective, the obstruction area must be located on
the posterior aspect of the pharynx and caused by the base of the
tongue.
2.3. Adjustment and placement of MAD
In this study Somnoﬁt (OCSIMED Swiss) MAD device was used.
This is a thermoplastic, adjustable MAD, with 6 levels of advancement.
We used advancement bands that can be gradually adapted and avoids
joint damage during the process of getting to the required advancement
level on each case (50–70% of the maximum protrusive). Patients were
informed also about the possible secondary eﬀects when using this
device and all signed a consent form.
The maximum level of advancement was independently assessed
for each case. One month after MAD collocation, patients were asked
about the event of side eﬀects for the use of MAD. Three months after
MAD collocation, once the patient and his bed partner reported an
evident clinical improvement, the next step was the PSG evaluation
with a SNP and MAD at the adequate advancement level.
2.4. Polysomnography
Patients were connected according to the International 10–20
system for electrodes placement for electroencephalography (EEG),
and the guidelines for the performance of respiratory polygraphy.
Registered variables were: electroencephalography, electrooculogra-
phy, electromyography, electrocardiography, thorax and abdominal
respiratory movements, air ﬂux by thermistor, oxygen saturation, body
position and lower extremities movements. PSG records were per-
formed using a Cadwell EEG-PSG equipment (Cadwell Industries,
Kennewick, WA).
During the ﬁrst 4 h, the patient was instructed not to use the MAD.
After 4 h, the patient was instructed to use it. PSG studies were
evaluated according to the American Academy of Sleep Medicine
Manual for the Scoring of sleep and Associated Events: Rules,
Terminology and Technical Speciﬁcations [27]. The following variables
were studied, before and during the use of MAD: Snoring index (SI),
Apnea-Hypopnea Index (AHI), Apnea index (AI), Hypopnea index (HI)
and oxygen (O2) saturation during Rapid eye movements sleep (REM)
and no-REM sleep.
We performed a SNP, half of night without MAD, and the other half
with MAD, because we wanted to know how much it could AHI change
to evaluate the patient for a full night, and during the 4 h of the divided
night. On the other hand, the SNP was consider an ideal tool in this
study, because besides not spend great resources, on a night it brings
help in diagnosis and therapeutic, allowing us to control changes in
important variables such weight, clinical characteristics, such as
obstruction of the airway by turbinate hypertrophy, temperature,
allergies, that during the diagnostic study did not show, getting more
realistic results.
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2.5. Statistics
For a study of 80% of power and signiﬁcance of 5%, a sample size of
28 patients was calculated. With data obtained from the question-
naires, a frequency analysis was performed. Central tendency measures
were also performed. Results were analyzed comparing the PSG
response in the same night before and during the use of MAD, with a
Student's t test, using SPSS 16.0 for Windows. Signiﬁcance was
determined with value of p≤0.05.
3. Results
Thirty patients were enrolled in this study, 16 men and 14 women,
with an average of 49.7 ± 12.45 years of age, and an average of body
mass index (BMI) of 27.84 ± 9.98 kg/m2. Median hours MAD use at
night was of 6 h (range 5–7 h). The results of SNP show signiﬁcant
changes with the use of MAD in the following variables (see Table 1):
SI, AHI, AI, and HI, showed a signiﬁcant decreased with the use of
MAD. Instead, O2 saturation during REM sleep and in no-REM sleep
showed a signiﬁcant increase. In ESS score, we found a signiﬁcant
improvement after patients used MAD for three months (see Table 2).
In the Bed partner questionnaire completed after the use of MAD, we
found that in all but one patient, snoring decreased, and in one third,
disappeared at all (see Table 3). Regarding side eﬀects with the use of
MAD, the main complaints manifested by patients were excessive
drooling and dental pain, in the half, and in the quarter of the sample
respectively (see Table 4).
4. Discussion
4.1. Main ﬁndings
The main contribution from this research was to show that MAD
careful selected in treatment of OSAHS was a reliable alternative in
their treatment, which was quantitatively veriﬁed by means of SNP in a
short-time prospective research. There is a controversy on MAD use in
literature, but our data showed signiﬁcant decrease in SI, AHI, AI, and
HI, and increase of O2 saturation in REM and no-REM sleep, and
improvement of other measurements, such as ESS and the Bed partner
questionnaire. Clinicians and patients will have the beneﬁt, provided by
have more tools for OSAHS treatment.
4.2. Comparison with other studies
SNP is commonly used in the diagnostic evaluation of OSAHS
patients and for titration of CPAP devices, watching the therapeutic
response during the same night. SNP gives the opportunity of an
assessment of eﬃcacy, while expenses and times are optimized, by
getting a basic diagnosis and therapeutic improvement in only one
night with the MAD.
We found a signiﬁcant decrease in the respiratory variables of sleep,
such as AHI, as well as it happened when SI, AI and HI who were
measured separately. Oxygen saturation showed a signiﬁcant increase
when using MAD, both, in REM and in non-REM sleep. Our data
conﬁrm results from other studies [28–30]. This fact supports our
approach of using the SNP as an important measurement tool. In this
study, we found that the levels of O2 saturation improved when using
MAD and this was not related to any sleep stage.
ESS showed a decrease in day-time somnolence of the patients,
after 3 months using MAD, this data was signiﬁcant too. Regarding the
responses reported by the Bed partner questionnaire, only one case
showed lack of improvement of snoring, but in 9 cases the bed partner
reported total absence of respiratory noise during sleep after MAD use,
as was reported previously [31,32].
Based on this information, we can say that success in the use of
MAD rely greatly on an accurate evaluation of the site of obstruction, as
well as the multidisciplinary approach and management. Follow up of
these patients is equally important, and SNP is a useful tool in the
accurate assessment of these patients.
In our study, we determined the eﬃcacy of MAD used in a Mexican
population, and we propose the use of SNP as a technique that allow us
to decrease expenses to both; the hospitals and the patients, getting in
only one night the chance to ﬁnd a basal result and therapeutic results
as well. This allows the proper clinical following of these patients. The
use of MAD in well selected patients, and its assessment with SNP
should be considered in a regular basis, as it would allow to a larger
number of patients and follow them taking in mind the decrease of
expenses in diagnosis and treatment.
Finally, the most commonly found side eﬀect was excessive drool-
ing, which lasted for about a month and then disappeared with no
treatment. The second most frequent side eﬀect was dental pain, which
was also self-limited. Four patients reported no side eﬀects. These
alterations had been reported previously in other investigations [33–
36].
4.3. Limitations of the study
These included the sample size, in futures studies we will increase
the number of studied patients. We are aware that SNP is not the only
one study to assess these patients, however, the high costs of complete
Table 1
Comparison of Splint night polysomnography (SNP) variables before and after use of
Mandibular advancement device (MAD).
Before MAD After MAD p
Snoring index 159.95 ± 30.46/h 32.46 ± 7.92/h 0.001
Apnea-hypopnea index 22.45 ± 6.14/h 4.63 ± 0.98/h 0.006
Obstructive apnea index 13.20 ± 3.70/h 3.5 ± 1.62/h 0.01
Hypopnea index 59.23 ± 9.29/h 16.46 ± 4.39/h 0.001
Oxygen saturation in no-Rapid eye
movements sleep
89.98 ± 0.84% 91.39 ± 0.43% 0.001
Oxygen saturation in Rapid eye
movements sleep
89.66 ± 0.67% 90.91 ± 0.58% 0.001
Table 2
Results of Epworth sleepiness scale before and after 3 months of Mandibular
advancement device (MAD) use.
Before MAD (points) After MAD (points) p
Epworth sleepiness scale 14.4 95 ± 4.18 4.6 95 ± 1.77 0.001
Table 3
Results from the Bed partner questionnaire after use of Mandibular advancement device
(MAD).
Snoring
disappearing
Persisted
mild snoring
Persisted
moderate
snoring
No changes
in snoring
Bed partner
answer
9 cases (30%) 11 cases
(36%)
9 cases (30%) 1 case (3%)
Table 4
Temporal side effects after use of Mandibular advancement device (MAD).
Side eﬀects Number of cases %
Excessive drooling 16 53
Dental pain 8 26
Articular pain 1 3
Muscular pain 1 3
No side eﬀects 4 13
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PSG or two, the few resources of our population, the awaiting for the
ﬁnal report, and not enough spaces in specialized clinics, led us to use a
simpliﬁed method such as SNP. With the resources available for this
study, it was less cost prohibitive to perform SNP for a two night study.
It has been demonstrated that the results in both modalities of studies
are comparable, when using CPAP therapy, and working like this, we
can save money and time, helping to improve waiting times that are
commonly found in sleep clinics.
5. Conclusions
The results of this study showed that split night polysomnography
is a useful tool for the use of alternatives such as oral devices, thus
allowing us to decrease expenses of both, in diagnosis and management
of this demographic of patients.
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